NCT03431090View on ClinicalTrials.gov

Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 2, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions
MyelodysplasiaHematologic Malignancy
Interventions
DEVICE

CliniMACS® TCRαβ/CD19 Combined Depletion System

The mobilized peripheral blood cell collection (apheresis product) will be processed using a Miltenyi CliniMACS device according to the manufacturing instructions. The processing will deplete the αβTCR+ cells and CD19+ cells from the apheresis product to formulate the graft.

Trial Locations (1)

43205

Nationwide Children's Hospital, Columbus

All Listed Sponsors
lead

Nationwide Children's Hospital

OTHER

NCT03431090 - Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia | Biotech Hunter | Biotech Hunter